Nicorandil: Pharmacology, Dosing, and Clinical Indications
Nicorandil is recommended at 10-20 mg twice daily for stable angina pectoris, particularly as second-line therapy when beta-blockers or calcium channel blockers are insufficient or not tolerated. 1
Pharmacology
Nicorandil is a unique antianginal agent with dual mechanism of action that distinguishes it from conventional therapies 1:
- Nitrate-like moiety: Dilates systemic veins and coronary arteries through nitric oxide donation, reducing preload
- Potassium channel activation: Opens mitochondrial ATP-sensitive potassium channels, which:
- Dilates peripheral and coronary resistance arterioles, increasing coronary blood flow
- Provides direct myocardial cytoprotection by mimicking ischemic preconditioning
- Protects ischemic myocytes during stress
This dual action affects both oxygen supply (coronary vasodilation) and demand (reduced preload/afterload) without impairing myocardial contractility or atrioventricular conduction 1.
Recommended Dosing
Standard regimen:
- Starting dose: 10 mg twice daily 1
- Maintenance dose: 20 mg twice daily 1
- Alternative low-start approach: 5 mg twice daily, then uptitrate to minimize headache 2
The twice-daily regimen provides sustained 24-hour antianginal coverage without development of tolerance 3, 4, 5.
Clinical Indications
Primary Indication: Stable Angina Pectoris
Second-line therapy when symptoms persist despite first-line treatment 6, 7:
- ESC 2006 Guidelines: Consider nicorandil as monotherapy when beta-blockers are not tolerated or poorly effective (Class IIa, Level C) 6
- ESC 2024 Guidelines: Nicorandil may be considered as add-on therapy with beta-blockers and/or calcium channel blockers, or as part of initial treatment in selected patients (Class IIb, Level B) 7
Efficacy: Comparable to beta-blockers, oral nitrates, and calcium channel blockers in reducing anginal frequency and improving exercise tolerance 1, 3, 4.
Vasospastic Angina
Nicorandil is useful for refractory vasospastic angina when high-dose calcium channel blockers and nitrates are insufficient 6. The AHA/ACC 2023 guidelines list nicorandil as third-line therapy for vasospastic angina (5 mg twice daily, uptitrated) 2.
Microvascular Angina (INOCA)
For patients with microvascular spasm: Nicorandil 5 mg twice daily, uptitrated, is recommended as third-line therapy after beta-blockers and calcium channel blockers 2.
Heart Failure with Angina
Use with caution: In patients with symptomatic heart failure (NYHA II-IV) and LV systolic dysfunction, nicorandil may be considered but safety is uncertain (Class IIb, Level C) 8. The ESC 2012 guidelines specifically note:
- NOT recommended in combination with ivabradine, ranolazine, or other nicorandil (Class III, Level C)
- NOT recommended with nitrates due to lack of additional efficacy (Class III, Level C) 8
Outcomes Data
The IONA trial (Impact of Nicorandil in Angina) demonstrated 1, 9:
- Reduced composite endpoint: 17% reduction in cardiovascular death, nonfatal MI, or unplanned hospitalization for chest pain (HR 0.83; 95% CI 0.72-0.97)
- Reduced acute coronary syndromes: 21% reduction (HR 0.79; 95% CI 0.64-0.98)
- No significant mortality benefit: Trend toward reduced mortality but not statistically significant (HR 0.79; 95% CI 0.61-1.02; P=0.07)
Critical limitation: The benefit was driven primarily by reduced hospitalizations for unstable angina, not by reductions in cardiovascular mortality or MI—the most clinically important outcomes 9.
Adverse Effects and Safety Considerations
Common adverse effects 9:
- Headache (most common): Occurs in ~33% of patients, typically mild-to-moderate, most frequent at initiation, improves with continued use
- Reflux, tachycardia, facial flushing, hypotension
Serious but rare 9:
- Skin, mucosal, and eye ulceration: Rare but serious complication
- Increased GI bleeding risk: When combined with aspirin, may increase risk of gastrointestinal ulcers, perforations, and hemorrhage 9
Withdrawal rate: Approximately 5% of patients discontinue due to headache; this can be minimized by starting at 5 mg twice daily 3.
Key Clinical Pearls
- No tolerance development: Unlike pure nitrates, nicorandil maintains efficacy with chronic use due to its potassium channel activation mechanism 3, 5
- Avoid nitrate combinations: Do not combine with long-acting nitrates in heart failure patients (no additional efficacy) 8
- Monitor for ulceration: Be vigilant for skin, mucosal, or eye ulcers during chronic therapy 9
- Aspirin interaction: Exercise caution when co-prescribing with aspirin due to increased GI bleeding risk 9
- Cost-effectiveness: In the UK, nicorandil was found cost-effective as additional costs were offset by reduced hospitalizations 1